Taking into consideration of the reduced suppressive activity of T regulatory cells (Treg) in MG (reflecting on elevated inflammatory cytokines in MG; Thiruppathi et al., 2012; Ha and Richman, 2015; Wen et al., 2016; Molin et al., 2017), the Treg-based therapy achieved with the use of IL-2/anti-IL-2 monoclonal antibody complexes could be useful for treating MG as shown by the experiment in experimental autoimmune MG (Liu et al., 2010; Danikowski et al., 2017). This evidence concerns the gene IL2 and myasthenia gravis.